Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Summary

This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced). Tumor treating fields therapy on this study utilizes NovoTTF systems that are wearable devices that use electrical fields at different frequencies that may help stop the growth of tumor cells by interrupting cancer cells' ability to divide.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Breast Carcinoma
• Advanced Endometrial Carcinoma
• Advanced Fallopian Tube Carcinoma
• Advanced Hepatocellular Carcinoma
• Advanced Malignant Abdominal Neoplasm
• Advanced Malignant Female Reproductive System Neoplasm
• Advanced Malignant Thoracic Neoplasm
• Advanced Ovarian Carcinoma
• Advanced Primary Peritoneal Carcinoma
• Advanced Renal Cell Carcinoma
• Anatomic Stage III Breast Cancer AJCC v8
• Anatomic Stage IIIA Breast Cancer AJCC v8
• Anatomic Stage IIIB Breast Cancer AJCC v8
• Anatomic Stage IIIC Breast Cancer AJCC v8
• Anatomic Stage IV Breast Cancer AJCC v8
• Malignant Abdominal Neoplasm
• Malignant Solid Neoplasm
• Metastatic Breast Carcinoma
• Metastatic Endometrial Carcinoma
• Metastatic Fallopian Tube Carcinoma
• Metastatic Hepatocellular Carcinoma
• Metastatic Malignant Abdominal Neoplasm
• Metastatic Malignant Female Reproductive System Neoplasm
• Metastatic Malignant Thoracic Neoplasm
• Metastatic Ovarian Carcinoma
• Metastatic Primary Peritoneal Carcinoma
• Metastatic Renal Cell Carcinoma
• Prognostic Stage III Breast Cancer AJCC v8
• Prognostic Stage IIIA Breast Cancer AJCC v8
• Prognostic Stage IIIB Breast Cancer AJCC v8
• Prognostic Stage IIIC Breast Cancer AJCC v8
• Prognostic Stage IV Breast Cancer AJCC v8
• Stage III Fallopian Tube Cancer AJCC v8
• Stage III Hepatocellular Carcinoma AJCC v8
• Stage III Ovarian Cancer AJCC v8
• Stage III Primary Peritoneal Cancer AJCC v8
• Stage III Renal Cell Cancer AJCC v8
• Stage III Uterine Corpus Cancer AJCC v8
• Stage IIIA Fallopian Tube Cancer AJCC v8
• Stage IIIA Hepatocellular Carcinoma AJCC v8
• Stage IIIA Ovarian Cancer AJCC v8
• Stage IIIA Primary Peritoneal Cancer AJCC v8
• Stage IIIA Uterine Corpus Cancer AJCC v8
• Stage IIIA1 Fallopian Tube Cancer AJCC v8
• Stage IIIA1 Ovarian Cancer AJCC v8
• Stage IIIA2 Fallopian Tube Cancer AJCC v8
• Stage IIIA2 Ovarian Cancer AJCC v8
• Stage IIIB Fallopian Tube Cancer AJCC v8
• Stage IIIB Hepatocellular Carcinoma AJCC v8
• Stage IIIB Ovarian Cancer AJCC v8
• Stage IIIB Primary Peritoneal Cancer AJCC v8
• Stage IIIB Uterine Corpus Cancer AJCC v8
• Stage IIIC Fallopian Tube Cancer AJCC v8
• Stage IIIC Ovarian Cancer AJCC v8
• Stage IIIC Primary Peritoneal Cancer AJCC v8
• Stage IIIC Uterine Corpus Cancer AJCC v8
• Stage IIIC1 Uterine Corpus Cancer AJCC v8
• Stage IIIC2 Uterine Corpus Cancer AJCC v8
• Stage IV Fallopian Tube Cancer AJCC v8
• Stage IV Hepatocellular Carcinoma AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Primary Peritoneal Cancer AJCC v8
• Stage IV Renal Cell Cancer AJCC v8
• Stage IV Uterine Corpus Cancer AJCC v8
• Stage IVA Fallopian Tube Cancer AJCC v8
• Stage IVA Hepatocellular Carcinoma AJCC v8
• Stage IVA Ovarian Cancer AJCC v8
• Stage IVA Primary Peritoneal Cancer AJCC v8
• Stage IVA Uterine Corpus Cancer AJCC v8
• Stage IVB Fallopian Tube Cancer AJCC v8
• Stage IVB Hepatocellular Carcinoma AJCC v8
• Stage IVB Ovarian Cancer AJCC v8
• Stage IVB Primary Peritoneal Cancer AJCC v8
• Stage IVB Uterine Corpus Cancer AJCC v8

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

M.D. Anderson Cancer Center

Last updated on ClinicalTrials.gov

July 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites